Johnson & Johnson (JNJ) Valuation

Based on the GoodMoat Investment Framework, the current price of $239.93 is 14.2% above the GoodMoat Target of $210.09. This results in a negative margin of safety, which places the stock in the 'Unfavourable' band according to the framework's DCF-based thresholds (which require a margin of safety of at least 20% for a 'Favourable' rating). The forward P/E of 21.6x is slightly above the typical sector average for large-cap pharmaceuticals and appears elevated relative to the company's 9.1% revenue growth, indicating the market is pricing in stability rather than deep value. Historically, J&J's P/E has often traded in the mid-to-high teens, making the current multiple at the higher end of its long-term range. While the company exhibits strong quality indicators like a robust ROE of 32.9% and a solid profit margin of 28.5%, the valuation assessment is critical. For a value investor seeking a margin of safety, the stock is not cheap; it is fairly valued to slightly expensive relative to its intrinsic value estimate and growth profile, requiring perfect execution to justify the price. Analysis based on data as of 2024-05-15.